Human Coagulation Factor VII Market , by Product (Recombinant Factor VII, Plasma Derived Factor VII) , by Application (Hemophilia, Surgery, Others), by End User (Hospitals, Ambulatory Surgical Centers, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033

Key Market Dynamics

The human coagulation factor VII market growth is expected, owing to rise in prevalence of bleeding diseases especially, hemophilia, and other bleeding illnesses, like congenital factor VII deficiency. For instance, according to the Centers for Disease Control and Prevention 33, 000 males are estimated to be living with hemophilia in the U.S. Hemophilia is associated with spontaneous bleeding and excessive bleeding after injury. This can include repeated bleeding within joints that can lead to chronic joint disease. Thus, the need for treatment is rising as a result of earlier diagnosis and greater awareness.

Further, the shift from plasma-derived to recombinant factor VII products, which offer higher safety profiles and reduced risk of infections, has significantly boosted the adoption of factor VII, thereby boosting the human coagulation factor VII market size . The growing geriatric population, which requires more frequent surgeries and medical interventions, is also further increasing the need for effective hemostatic agents like factor VII to prevent or manage bleeding. Moreover, factor VII products are increasingly being used for off-label indications, such as managing uncontrolled bleeding in surgeries, trauma, and patients on anticoagulant therapy. Thus, this broader clinical application is driving demand.

Further, factor VII is also often used to control bleeding in trauma patients and in critical care scenarios where blood loss needs to be rapidly managed, leading to greater utilization in emergency settings. Furthermore, the regulatory environment has been supportive, with new and improved Factor VII products gaining approval for expanded therapeutic uses, further driving the market. The expansion of healthcare infrastructure and increased access to advanced therapies in emerging markets, particularly in Asia-Pacific and Latin America, are contributing to the human coagulation factor VII market opportunity.

Patent Analysis Human Coagulation Factor VII Market

Although the human coagulation factor VII market growth has been more rapid in recent years, the industry can draw on the patents filed by various companies. For instance, patents filed by the companies based in the U.S. dominated with a 22.2% share, European Patent Office holds a share of 17.2%, Patent Cooperation Treaty (PCT) holds a share of about 14.9%, China holds a share of about 10.9%, and others holds a share of about 19.5%.

Market Segmentation

The human coagulation factor VII market analysis is segmented into product, application, end user, and region. On the basis of product, the market is categorized into recombinant factor VII and plasma derived factor VII. On the basis of application, the market is categorized into hemophilia, surgery, and others. On the basis of end user, the market is categorized into hospitals, ambulatory surgical centers, and others. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Regional/Country Market Outlook

North America accounted for a major human coagulation factor VII market share owing to the presence of major players, drug approval, well-established healthcare facilities, rise in technological advancements, and rise in demand for early diagnosis of hemophilia and other bleeding disorders due to increase in awareness regarding the disease.?

Asia-Pacific human coagulation factor VII market share is estimated to grow with the highest CAGR during the forecast period, owing to rise in target population. Another factor driving the growth of the market is the focus of major players on technological advancements, expansion via generic product development, and approval in the human coagulation factor VII market.

Industry Trends

• Government initiatives to reduce healthcare costs and improve access to therapies are expected to hamper the prices of factor VII products. Cost-effective biosimilars and reimbursement policies could impact the market growth.
• Treatments for patients with particular coagulation disorders are increasingly being customized based on their genetic profiles and unique demands. Patients with factor VII deficiency may benefit from personalized therapy, which would increase demand for customized factor VII formulations.

Competitive Landscape

The major players operating in the human coagulation factor VII market are Baxter International Inc., Bayer AG, Pfizer Inc, CSL Behring, Grifols USA LLC, Novo Nordisk, Octapharma AG, ProSpec, Sanofi, and Tany Technogene Ltd.

Key Sources Referred

• National Center for Biotechnology Information
• World Health Organization (WHO)
• National Library of Medicine
• The United States Food and Drug Administration
• U.S. Department of Health & Human Services
• Centers for Disease Control and Prevention
• Indian Council of Medical Research
• World Federation of Hemophilia
• National Organization for Rare Disorders
• Australian Bureau of Statistics

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the market analysis from 2024 to 2033 to identify the prevailing market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the market segmentation assists to determine the prevailing market opportunities and human coagulation factor VII market forecast.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global human coagulation factor vii market trends, key players, market segments, application areas, and market growth strategies.